Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Seminars in Immunopathology
Erschienen in: Seminars in Immunopathology 2/2009

01.07.2009 | Review

Immune cell-mediated liver injury

verfasst von: Nadia Corazza, Anastasia Badmann, Christoph Lauer

Erschienen in: Seminars in Immunopathology | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Liver diseases represent an important cause of morbidity and mortality in the world. Death of hepatocytes and other hepatic cell types is a characteristic feature of several forms of liver injury such as cholestasis, viral hepatitis, drug- or toxin-induced injury, and alcohol-induced liver damage. Moreover, irrespectively of the reason, liver injury seems to be facilitated by similar immune effector mechanisms common to these various liver diseases. Indeed, common immune effector mechanisms may explain the high prevalence of cirrhosis and cancer development in most forms of liver disease. Improved understanding of the immune cell-mediated mechanisms involved in hepatocyte cell death could be beneficial for the development of common therapeutic strategies against different forms of liver diseases. In this review, we will discuss novel findings on the role of different immune cells in liver disease and immune cell-induced death executioner mechanisms involved in hepatocyte cell death.
Literatur
1.
Benseler V, McCaughan GW, Schlitt HJ, Bishop GA, Bowen DG, Bertolino P (2007) The liver: a special case in transplantation tolerance. Semin Liver Dis 27:194–213CrossRefPubMed
2.
Knolle PA (2006) Involvement of the liver in the induction of CD8 T cell tolerance towards oral antigen. Z Gastroenterol 44:51–56CrossRefPubMed
3.
Bahjat KS, Prell RA, Allen HE, Liu W, Lemmens EE, Leong ML, Portnoy DA, Dubensky TW Jr, Brockstedt DG, Giedlin MA (2007) Activation of immature hepatic NK cells as immunotherapy for liver metastatic disease. J Immunol 179:7376–7384PubMed
4.
Takeda K, Seki S, Ogasawara K, Anzai R, Hashimoto W, Sugiura K, Takahashi M, Satoh M, Kumagai K (1996) Liver NK1.1+ CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. J Immunol 156:3366–3373PubMed
5.
Emmanuilidis K, Weighardt H, Maier S, Gerauer K, Fleischmann T, Zheng XX, Hancock WW, Holzmann B, Heidecke CD (2001) Critical role of Kupffer cell-derived IL-10 for host defense in septic peritonitis. J Immunol 167:3919–3927PubMed
6.
Kurachi K, Suzuki S, Sakaguchi T, Yokoi Y, Konno H, Baba S, Nakamura S (2003) Kupffer cells modulate splenic interleukin-10 production in endotoxin-induced liver injury after partial hepatectomy. J Hepatol 38:193–199CrossRefPubMed
7.
Rai RM, Loffreda S, Karp CL, Yang SQ, Lin HZ, Diehl AM (1997) Kupffer cell depletion abolishes induction of interleukin-10 and permits sustained overexpression of tumor necrosis factor alpha messenger RNA in the regenerating rat liver. Hepatology 25:889–895CrossRefPubMed
8.
Tiegs G, Hentschel J, Wendel A (1992) A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 90:196–203CrossRefPubMed
9.
Bonder CS, Ajuebor MN, Zbytnuik LD, Kubes P, Swain MG (2004) Essential role for neutrophil recruitment to the liver in concanavalin A-induced hepatitis. J Immunol 172:45–53PubMed
10.
Hatada S, Ohta T, Shiratsuchi Y, Hatano M, Kobayashi Y (2005) A novel accessory role of neutrophils in concanavalin A-induced hepatitis. Cell Immunol 233:23–29CrossRefPubMed
11.
Hatano M, Sasaki S, Ohata S, Shiratsuchi Y, Yamazaki T, Nagata K, Kobayashi Y (2008) Effects of Kupffer cell-depletion on concanavalin A-induced hepatitis. Cell Immunol 251:25–30CrossRefPubMed
12.
Schumann J, Wolf D, Pahl A, Brune K, Papadopoulos T, van Rooijen N, Tiegs G (2000) Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am J Pathol 157:1671–1683PubMed
13.
Gantner F, Leist M, Lohse AW, Germann PG, Tiegs G (1995) Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology 21:190–198PubMed
14.
Kusters S, Gantner F, Kunstle G, Tiegs G (1996) Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 111:462–471CrossRefPubMed
15.
Kusters S, Tiegs G, Alexopoulou L, Pasparakis M, Douni E, Kunstle G, Bluethmann H, Wendel A, Pfizenmaier K, Kollias G, Grell M (1997) In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol 27:2870–2875CrossRefPubMed
16.
Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K (2001) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 193:661–670CrossRefPubMed
17.
Tagawa Y, Kakuta S, Iwakura Y (1998) Involvement of Fas/Fas ligand system-mediated apoptosis in the development of concanavalin A-induced hepatitis. Eur J Immunol 28:4105–4113CrossRefPubMed
18.
Jiang W, Sun R, Wei H, Tian Z (2005) Toll-like receptor 3 ligand attenuates LPS-induced liver injury by down-regulation of toll-like receptor 4 expression on macrophages. Proc Natl Acad Sci U S A 102:17077–17082CrossRefPubMed
19.
Nolan JP (1975) The role of endotoxin in liver injury. Gastroenterology 69:1346–1356PubMed
20.
Nolan JP (1989) Intestinal endotoxins as mediators of hepatic injury—an idea whose time has come again. Hepatology 10:887–891CrossRefPubMed
21.
Nolan JP, Camara DS (1989) Intestinal endotoxins as co-factors in liver injury. Immunol Invest 18:325–337CrossRefPubMed
22.
Luster MI, Germolec DR, Yoshida T, Kayama F, Thompson M (1994) Endotoxin-induced cytokine gene expression and excretion in the liver. Hepatology 19:480–488CrossRefPubMed
23.
Adachi Y, Bradford BU, Gao W, Bojes HK, Thurman RG (1994) Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology 20:453–460CrossRefPubMed
24.
Dong Z, Wei H, Sun R, Hu Z, Gao B, Tian Z (2004) Involvement of natural killer cells in PolyI:C-induced liver injury. J Hepatol 41:966–973CrossRefPubMed
25.
Ochi M, Ohdan H, Mitsuta H, Onoe T, Tokita D, Hara H, Ishiyama K, Zhou W, Tanaka Y, Asahara T (2004) Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. Hepatology 39:1321–1331CrossRefPubMed
26.
Malhi H, Gores GJ (2008) Cellular and molecular mechanisms of liver injury. Gastroenterology 134:1641–1654CrossRefPubMed
27.
Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S (1994) Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969–976CrossRefPubMed
28.
Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314–317CrossRefPubMed
29.
Adachi M, Suematsu S, Kondo T, Ogasawara J, Tanaka T, Yoshida N, Nagata S (1995) Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 11:294–300CrossRefPubMed
30.
Zender L, Hutker S, Liedtke C, Tillmann HL, Zender S, Mundt B, Waltemathe M, Gosling T, Flemming P, Malek NP, Trautwein C, Manns MP, Kuhnel F, Kubicka S (2003) Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A 100:7797–7802CrossRefPubMed
31.
Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364:806–809CrossRefPubMed
32.
Batey RG, Wang J (2002) Molecular pathogenesis of T lymphocyte-induced liver injury in alcoholic hepatitis. Front Biosci 7:d1662–d1675CrossRefPubMed
33.
Liu ZX, Han D, Gunawan B, Kaplowitz N (2006) Neutrophil depletion protects against murine acetaminophen hepatotoxicity. Hepatology 43:1220–1230CrossRefPubMed
34.
Kaneko Y, Harada M, Kawano T, Yamashita M, Shibata Y, Gejyo F, Nakayama T, Taniguchi M (2000) Augmentation of Valpha14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med 191:105–114CrossRefPubMed
35.
Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, Fusamoto H, Kamada T (1994) Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 19:1354–1359CrossRefPubMed
36.
Bode JG, Brenndorfer ED, Haussinger D (2008) Hepatitis C virus (HCV) employs multiple strategies to subvert the host innate antiviral response. Biol Chem 389:1283–1298CrossRefPubMed
37.
Chou AH, Tsai HF, Wu YY, Hu CY, Hwang LH, Hsu PI, Hsu PN (2005) Hepatitis C virus core protein modulates TRAIL-mediated apoptosis by enhancing Bid cleavage and activation of mitochondria apoptosis signaling pathway. J Immunol 174:2160–2166PubMed
38.
Iio S, Hayashi N, Mita E, Ueda K, Mochizuki K, Hiramatsu N, Kanto T, Sasaki Y, Kasahara A, Hori M (1998) Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol 29:517–523CrossRefPubMed
39.
Pianko S, Patella S, Ostapowicz G, Desmond P, Sievert W (2001) Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. J Viral Hepat 8:406–413CrossRefPubMed
40.
Sacco R, Tsutsumi T, Suzuki R, Otsuka M, Aizaki H, Sakamoto S, Matsuda M, Seki N, Matsuura Y, Miyamura T, Suzuki T (2003) Antiapoptotic regulation by hepatitis C virus core protein through up-regulation of inhibitor of caspase-activated DNase. Virology 317:24–35CrossRefPubMed
41.
Minagawa M, Deng Q, Liu ZX, Tsukamoto H, Dennert G (2004) Activated natural killer T cells induce liver injury by Fas and tumor necrosis factor-alpha during alcohol consumption. Gastroenterology 126:1387–1399CrossRefPubMed
42.
Tagami A, Ohnishi H, Moriwaki H, Phillips M, Hughes RD (2003) Fas-mediated apoptosis in acute alcoholic hepatitis. Hepatogastroenterology 50:443–448PubMed
43.
Miyoshi H, Rust C, Roberts PJ, Burgart LJ, Gores GJ (1999) Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology 117:669–677CrossRefPubMed
44.
Hatano E (2007) Tumor necrosis factor signaling in hepatocyte apoptosis. J Gastroenterol Hepatol 22(Suppl 1):S43–S44CrossRefPubMed
45.
MacEwan DJ (2002) TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 14:477–492CrossRefPubMed
46.
Yamada Y, Kirillova I, Peschon JJ, Fausto N (1997) Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci U S A 94:1441–1446CrossRefPubMed
47.
Yamada Y, Webber EM, Kirillova I, Peschon JJ, Fausto N (1998) Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: requirement for type 1 but not type 2 receptor. Hepatology 28:959–970CrossRefPubMed
48.
Costelli P, Aoki P, Zingaro B, Carbo N, Reffo P, Lopez-Soriano FJ, Bonelli G, Argiles JM, Baccino FM (2003) Mice lacking TNFalpha receptors 1 and 2 are resistant to death and fulminant liver injury induced by agonistic anti-Fas antibody. Cell Death Differ 10:997–1004CrossRefPubMed
49.
Kaufmann T, Jost PJ, Pellegrini M, Puthalakath H, Gugasyan R, Gerondakis S, Cretney E, Smyth MJ, Silke J, Hakem R, Bouillet P, Mak TW, Dixit VM, Strasser A (2009) Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim. Immunity 30:56–66CrossRefPubMed
50.
Luedde T, Heinrichsdorff J, de Lorenzi R, De Vos R, Roskams T, Pasparakis M (2008) IKK1 and IKK2 cooperate to maintain bile duct integrity in the liver. Proc Natl Acad Sci U S A 105:9733–9738CrossRefPubMed
51.
Wullaert A, Heyninck K, Beyaert R (2006) Mechanisms of crosstalk between TNF-induced NF-kappaB and JNK activation in hepatocytes. Biochem Pharmacol 72:1090–1101CrossRefPubMed
52.
Javelaud D, Besancon F (2001) NF-kappa B activation results in rapid inactivation of JNK in TNF alpha-treated Ewing sarcoma cells: a mechanism for the anti-apoptotic effect of NF-kappa B. Oncogene 20:4365–4372CrossRefPubMed
53.
Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M, Lin A (2001) Inhibition of JNK activation through NF-kappaB target genes. Nature 414:313–317CrossRefPubMed
54.
De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R, Jones J, Cong R, Franzoso G (2001) Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature 414:308–313CrossRefPubMed
55.
Schwabe RF, Uchinami H, Qian T, Bennett BL, Lemasters JJ, Brenner DA (2004) Differential requirement for c-Jun NH2-terminal kinase in TNF-alpha- and Fas-mediated apoptosis in hepatocytes. FASEB J 18:720–722PubMed
56.
Marderstein EL, Bucher B, Guo Z, Feng X, Reid K, Geller DA (2003) Protection of rat hepatocytes from apoptosis by inhibition of c-Jun N-terminal kinase. Surgery 134:280–284CrossRefPubMed
57.
Ni HM, Chen X, Shi YH, Liao Y, Beg AA, Fan J, Yin XM (2009) Genetic delineation of the pathways mediated by bid and JNK in tumor necrosis factor-alpha-induced liver injury in adult and embryonic mice. J Biol Chem 284:4373–4382CrossRefPubMed
58.
Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, Liu YC, Karin M (2006) The E3 ubiquitin ligase itch couples JNK activation to TNF-alpha-induced cell death by inducing c-FLIP(L) turnover. Cell 124:601–613CrossRefPubMed
59.
Das M, Sabio G, Jiang F, Rincon M, Flavell RA, Davis RJ (2009) Induction of hepatitis by JNK-mediated expression of TNF-alpha. Cell 136:249–260CrossRefPubMed
60.
Kim YS, Morgan MJ, Choksi S, Liu ZG (2007) TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Mol Cell 26:675–687CrossRefPubMed
61.
Guo Y, Chen C, Zheng Y, Zhang J, Tao X, Liu S, Zheng D, Liu Y (2005) A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J Biol Chem 280:41940–41952CrossRefPubMed
62.
Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, Zhou T (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7:954–960CrossRefPubMed
63.
Corazza N, Jakob S, Schaer C, Frese S, Keogh A, Stroka D, Kassahn D, Torgler R, Mueller C, Schneider P, Brunner T (2006) TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality. J Clin Invest 116:2493–2499CrossRefPubMed
64.
Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157–163CrossRefPubMed
65.
Fandy TE, Shankar S, Srivastava RK (2008) Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer 7:60CrossRefPubMed
66.
Sugamura K, Gibbs JF, Belicha-Villanueva A, Andrews C, Repasky EA, Hylander BL (2008) Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts. Oncology 74:188–197CrossRefPubMed
67.
Fulda S, Debatin KM (2006) 5-Aza-2′-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene 25:5125–5133CrossRefPubMed
68.
Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC (2001) TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98:795–804CrossRefPubMed
69.
Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K (2001) Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7:94–100CrossRefPubMed
70.
Sedger LM, Glaccum MB, Schuh JC, Kanaly ST, Williamson E, Kayagaki N, Yun T, Smolak P, Le T, Goodwin R, Gliniak B (2002) Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J Immunol 32:2246–2254CrossRefPubMed
71.
Seki N, Hayakawa Y, Brooks AD, Wine J, Wiltrout RH, Yagita H, Tanner JE, Smyth MJ, Sayers TJ (2003) Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res 63:207–213PubMed
72.
Zheng SJ, Wang P, Tsabary G, Chen YH (2004) Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest 113:58–64PubMed
73.
Tagawa Y, Sekikawa K, Iwakura Y (1997) Suppression of concanavalin A-induced hepatitis in IFN-gamma(−/−) mice, but not in TNF-alpha(−/−) mice: role for IFN-gamma in activating apoptosis of hepatocytes. J Immunol 159:1418–1428PubMed
74.
Wang S, Boonman ZF, Li HC, He Y, Jager MJ, Toes RE, Niederkorn JY (2003) Role of TRAIL and IFN-gamma in CD4+ T cell-dependent tumor rejection in the anterior chamber of the eye. J Immunol 171:2789–2796PubMed
75.
Kahraman A, Barreyro FJ, Bronk SF, Werneburg NW, Mott JL, Akazawa Y, Masuoka HC, Howe CL, Gores GJ (2008) TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. Hepatology 47:1317–1330CrossRefPubMed
76.
Mundt B, Kuhnel F, Zender L, Paul Y, Tillmann H, Trautwein C, Manns MP, Kubicka S (2003) Involvement of TRAIL and its receptors in viral hepatitis. FASEB J 17:94–96PubMed
77.
Janssen HL, Higuchi H, Abdulkarim A, Gores GJ (2003) Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. J Hepatol 39:414–420CrossRefPubMed
78.
Chen GY, He JQ, Lu GC, Li MW, Xu CH, Fan WW, Zhou C, Chen Z (2005) Association between TRAIL expression on peripheral blood lymphocytes and liver damage in chronic hepatitis B. World J Gastroenterol 11:4090–4093PubMed
79.
Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, Miyazoe S, Nakagawa Y, Ishikawa H, Hamasaki K, Nakata K, Ishii N, Eguchi K (2003) Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene 22:1653–1662CrossRefPubMed
80.
Sato K, Hida S, Takayanagi H, Yokochi T, Kayagaki N, Takeda K, Yagita H, Okumura K, Tanaka N, Taniguchi T, Ogasawara K (2001) Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol 31:3138–3146CrossRefPubMed
81.
Malhi H, Barreyro FJ, Isomoto H, Bronk SF, Gores GJ (2007) Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut 56:1124–1131CrossRefPubMed
82.
Lan L, Gorke S, Rau SJ, Zeisel MB, Hildt E, Himmelsbach K, Carvajal-Yepes M, Huber R, Wakita T, Schmitt-Graeff A, Royer C, Blum HE, Fischer R, Baumert TF (2008) Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner. J Immunol 181:4926–4935PubMed
83.
Liang X, Liu Y, Zhang Q, Gao L, Han L, Ma C, Zhang L, Chen YH, Sun W (2007) Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax. J Immunol 178:503–510PubMed
84.
Liu ZX, Govindarajan S, Kaplowitz N (2004) Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 127:1760–1774CrossRefPubMed
85.
Kaufmann T, Tai L, Ekert PG, Huang DC, Norris F, Lindemann RK, Johnstone RW, Dixit VM, Strasser A (2007) The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. Cell 129:423–433CrossRefPubMed
86.
Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, Roth KA, Korsmeyer SJ (1999) Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400:886–891CrossRefPubMed
87.
Zhao Y, Li S, Childs EE, Kuharsky DK, Yin XM (2001) Activation of pro-death Bcl-2 family proteins and mitochondria apoptosis pathway in tumor necrosis factor-alpha-induced liver injury. J Biol Chem 276:27432–27440CrossRefPubMed
88.
Hanawa N, Shinohara M, Saberi B, Gaarde WA, Han D, Kaplowitz N (2008) Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury. J Biol Chem 283:13565–13577CrossRefPubMed
89.
Malhi H, Bronk SF, Werneburg NW, Gores GJ (2006) Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 281:12093–12101CrossRefPubMed
90.
Wang Y, Singh R, Lefkowitch JH, Rigoli RM, Czaja MJ (2006) Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway. J Biol Chem 281:15258–15267CrossRefPubMed
91.
Ley R, Ewings KE, Hadfield K, Cook SJ (2005) Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ 12:1008–1014CrossRefPubMed
92.
El-Hassan H, Anwar K, Macanas-Pirard P, Crabtree M, Chow SC, Johnson VL, Lee PC, Hinton RH, Price SC, Kass GE (2003) Involvement of mitochondria in acetaminophen-induced apoptosis and hepatic injury: roles of cytochrome c, Bax, Bid, and caspases. Toxicol Appl Pharmacol 191:118–129CrossRefPubMed
93.
Nakagawa H, Maeda S, Hikiba Y, Ohmae T, Shibata W, Yanai A, Sakamoto K, Ogura K, Noguchi T, Karin M, Ichijo H, Omata M (2008) Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology 135:1311–1321CrossRefPubMed
Metadaten
Titel
Immune cell-mediated liver injury
verfasst von
Nadia Corazza
Anastasia Badmann
Christoph Lauer
Publikationsdatum
01.07.2009
Verlag
Springer-Verlag
Erschienen in
Seminars in Immunopathology / Ausgabe 2/2009
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-009-0168-1

Weitere Artikel der Ausgabe 2/2009

Seminars in Immunopathology 2/2009 Zur Ausgabe

Review

Intestinal macrophages: differentiation and involvement in intestinal immunopathologies

Review

Disturbance of the gut-associated lymphoid tissue is associated with disease progression in chronic HIV infection

Review

Physiological and pathophysiological functions of intestinal mast cells

Review

Colitis-associated cancer: the role of T cells in tumor development

Review

Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners

Review

Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

10.05.2024 Periphere arterielle Verschlusskrankheit Nachrichten

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise